Study guide

10.3 Radiation Therapy, I-131-MIBG, and Proton Beam

Certified Pediatric Hematology Oncology Nurse CPHON®

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 Current Exam Facts 1.2 Eligibility, Application, and Testing Logistics 1.3 Test Content Outline and Study Strategy

2 Care Continuum

2.1 Transition of Care: Primary Care and Levels of Care 2.2 End-of-Life Care 2.3 Health Promotion and Maintenance 2.4 Survivorship

3 Leukemias and Lymphomas

3.1 Acute Lymphoblastic Leukemia 3.2 Acute Myeloid Leukemia and Related Myeloid Disease 3.3 Hodgkin and Non-Hodgkin Lymphomas

4 CNS, Neuroblastoma, and Renal Tumors

4.1 Central Nervous System Tumors 4.2 Neuroblastoma 4.3 Wilms Tumor and Other Renal Tumors

5 Sarcomas and Other Solid Tumors

5.1 Osteosarcoma and Ewing Sarcoma 5.2 Rhabdomyosarcoma and Soft-Tissue Sarcomas 5.3 Retinoblastoma, Hepatoblastoma, and Germ Cell Tumors

6 Hematologic Disorders

6.1 Sickle Cell Disease 6.2 Thalassemia and Other Hemoglobinopathies 6.3 Hemophilia, von Willebrand Disease, and Coagulopathies 6.4 Immune Thrombocytopenia, Aplastic Anemia, and Bone Marrow Failure

7 Pathophysiology, Genetics, and Diagnostics

7.1 Anatomy, Physiology, and Pathophysiology Foundations 7.2 Genetics and Genomics 7.3 Diagnostic Testing, Staging, and Prognosis

8 Clinical Trials and Professional Performance

8.1 Clinical Trials and Informed Consent 8.2 Scope, Standards, and Regulatory Practice 8.3 Ethics and Patient-Family Education

9 Chemotherapy and Biotherapy

9.1 Chemotherapy Principles, Classes, and Pediatric Protocols 9.2 Safe Handling, Administration, and Vesicant Precautions 9.3 Biotherapy

10 Immunotherapy, Cellular Therapy, and Radiation

10.1 Immunotherapy 10.2 Cellular Therapies including CAR-T 10.3 Radiation Therapy, I-131-MIBG, and Proton Beam

11 HSCT, Surgery, Transfusion, and Coagulation Therapy

11.1 Hematopoietic Stem Cell Transplantation 11.2 Surgical Management 11.3 Blood Product Therapy, Leukapheresis, and Coagulation Therapy

12 Neurologic, Respiratory, and Cardiovascular Effects

12.1 Neurological Acute, Chronic, and Late Effects 12.2 Respiratory and Lymphatic Effects 12.3 Cardiovascular Effects

13 Gastrointestinal, Renal, Musculoskeletal, and Integumentary Effects

13.1 Gastrointestinal Effects 13.2 Renal and Genitourinary Effects 13.3 Musculoskeletal and Integumentary Effects

14 Endocrine, Hematologic, Immunologic, and Sensory Effects

14.1 Endocrine and Reproductive Effects 14.2 Hematological and Immunological Effects 14.3 Ophthalmological and Otological Effects

15 Pain, Sleep, Fatigue, and Mental Health

15.1 Pain Assessment and Management 15.2 Sleep Disturbance and Fatigue 15.3 Mental Health Effects

16 Supportive Care

16.1 Medical Devices: Venous Access, Pumps, Shunts, and Tubes 16.2 Blood Product Administration 16.3 Colony-Stimulating Factors 16.4 Interdisciplinary, Palliative, and Complementary Care

17 Infectious and Gastrointestinal Emergencies

17.1 Sepsis 17.2 Typhlitis 17.3 Pancreatitis and Bowel Obstruction

18 Metabolic Emergencies

18.1 Diabetes Insipidus and SIADH 18.2 Tumor Lysis Syndrome 18.3 Cytokine Release Syndrome

19 DIC, Hyperleukocytosis, and Sinusoidal Obstructive Syndrome

19.1 Disseminated Intravascular Coagulation and Hemorrhage 19.2 Hyperleukocytosis 19.3 Sinusoidal Obstructive Syndrome (Veno-Occlusive Disease)

20 Sickle Cell and Hemostasis Emergencies

20.1 Splenic Sequestration 20.2 Vaso-Occlusive Crisis 20.3 Stroke, Thrombosis, and Joint Bleed

21 Cardiopulmonary Emergencies

21.1 Acute Chest Syndrome 21.2 Respiratory Distress and Mediastinal Mass 21.3 Pleural Effusions and Arrhythmias

22 Neurologic and Infusion Emergencies

22.1 Increased Intracranial Pressure 22.2 Seizures and PRES 22.3 Spinal Cord Compression 22.4 Hypersensitivity Reactions and Extravasation

23 Family, Caregivers, and Social Integration

23.1 Effects of Acute and Chronic Illness on Patient and Family 23.2 Patient and Family/Caregiver Support 23.3 Integration into Family, School, Work, Camp, and Social Environment

24 Development, Grief, Culture, and Community Resources

24.1 Principles of Growth and Development 24.2 Grief and Bereavement 24.3 Culture, Sexuality and Gender, Socioeconomics, and Community Resources

10.3 Radiation Therapy, I-131-MIBG, and Proton Beam

Key Takeaways Explain This Topic AI

Photon beams deposit exit dose; proton beams stop at the Bragg peak and can spare developing tissue such as cochlea, heart, and contralateral breast, but late effects are reduced, not erased.

Pediatric daily radiation requires immobilization, skin marks or tattoos that must not be washed off, anesthesia for young children, and NPO per anesthesia rules.

Acute effects include dermatitis, mucositis, somnolence syndrome after cranial radiation, esophagitis, diarrhea, and cytopenias when a large marrow field, CSI, or TBI is treated.

Late effects include impaired growth in the field, endocrinopathy, neurocognitive change, secondary malignancy, and infertility; CSI and TBI have additional nursing loads.

I-131-MIBG requires potassium iodide thyroid blockade, isolation and caregiver exposure limits per radiation-safety orders, contamination control, and handling of catheters and diapers as radioactive waste—never invent a single isolation-day number as ONCC fact.

Last updated: August 2026

Radiation is local control with a beam or a targeted isotope. CPHON TCO III.B.6 tests whether you can explain photons versus protons , get a toddler through daily anesthesia and immobilization, name acute versus late effects, nurse craniospinal fields and total body irradiation (TBI) , and run an iodine-131 metaiodobenzylguanidine (I-131-MIBG) isolation room without inventing an official isolation-day number.

Photons versus protons: Bragg peak and developing tissue

Photon (x-ray) beams deposit dose on the way in and on the way out. Exit dose is the pediatric problem: cochlea, heart, lungs, thyroid, and contralateral breast sit in the path of yesterday's technology.

Proton beams deposit most of their energy at a finite depth—the Bragg peak —then stop. That is why protons are used to spare developing tissue : cochlear sparing in central-nervous-system and head-and-neck fields, cardiac and lung sparing in mediastinal or left-chest fields, and contralateral-breast and gonad sparing when anatomy allows. Protons are a delivery method, not a different diagnosis. They reduce —they do not erase—growth delay, endocrinopathy, neurocognitive change, or secondary malignancy. A family who hears "protons mean no late effects" has been mistaught. Not every child who would benefit can travel to a proton center; COG protocols specify when protons are preferred versus allowed. Do not teach that photons are malpractice.

A 6-year-old receiving craniospinal radiation for medulloblastoma is the classic Bragg-peak conversation: spare cochlea, heart, and thyroid as much as geometry allows, still plan hearing tests, growth-hormone surveillance, and school supports.

Daily treatment: immobilization, marks, anesthesia, NPO

Radiation is fractionated: small daily doses over days to weeks. Children must lie still. Immobilization uses thermoplastic masks, vac-locks, and custom cushions. Tattoos or skin marks are millimeters that aim the beam; do not scrub them off as dirt, and teach families not to apply unapproved lotions that smear the field. Some centers use temporary marks rather than permanent ink; either way, the marks stay until radiation oncology says otherwise.

A 3-year-old cannot hold a mask for 20 minutes: daily anesthesia (often propofol-based) is common. That means nothing by mouth (NPO) each treatment morning per anesthesia rules , an intravenous or port access plan, recovery-room time, and a family schedule that is a second job. Do not invent a single national NPO hour as ONCC fact; follow anesthesia. Missed fractions because "the child ate cereal" delay local control. Hydrate and plan calories around the NPO window; do not let a toddler go from radiation recovery onto an empty-stomach chemotherapy day without a nutrition plan.

Skin in the field is irradiated skin: wash gently, no scented alcohol wipes, no heating pads, and use only the radiation-oncology–approved moisturizer. A 5-year-old in a CSI mask who must be NPO at dawn is living this section, not a worksheet about linear accelerators.

Acute effects

  • Field or situation Acute effect Nursing
  • Skin in beam Radiation dermatitis Gentle care, pain, infection watch
  • Head and neck, CSI Mucositis, thick saliva, taste change Mouth care, feeding support, opioids as needed

Cranial Somnolence syndrome (subacute lethargy after cranial RT) Safety, school excuse; not automatically relapse

  • Thorax or mediastinum Esophagitis Painful swallow, nutrition, reflux plan
  • Abdomen or pelvis Diarrhea, nausea, cystitis Fluids, perineal skin care, output
  • Large marrow field, CSI, TBI Cytopenias CBC, transfusions, infection precautions
  • TBI All of the above plus parotitis and fever HSCT-unit supportive care

Somnolence syndrome after cranial radiation is a child who, days to a couple of weeks after the course, sleeps excessively, is irritable, and looks "not themselves" without a new mass on emergency imaging. It is usually self-limited. Teach it so families do not hear only "the tumor is back." Still notify—because infection, endocrine crisis, and true progression also cause sleepiness. A 7-year-old who sleeps through meals two weeks after cranial radiation needs that differential, not a shrug and not an automatic declaration of relapse.

Late effects: the reason pediatric radiation is rationed

Developing bone in the field grows less —asymmetric spine after flank radiation, short sitting height after CSI, hypoplasia of the treated face. Endocrine failure follows hypothalamic-pituitary or thyroid dose: growth hormone, thyroid-stimulating hormone, adrenocorticotropic hormone, gonadotropins. Neurocognitive change (processing speed, attention) after brain dose needs 504 or individualized education program planning. Secondary malignancy (breast, thyroid, sarcoma, brain) is a decades-long risk; teach surveillance, not a made-up percentage. Infertility follows gonadal or hypothalamic dose and TBI; fertility-preservation conversations belong before the first fraction when feasible. Photons versus protons change the probability, not the counseling duty.

Craniospinal radiation and TBI

Craniospinal irradiation (CSI) treats the whole neuraxis for tumors that seed cerebrospinal fluid (classic: medulloblastoma in children old enough to receive it). The brain field is matched to a spine field. Nursing specifics: nausea is often worse than for a small local field—give antiemetics before the fraction; bone marrow in the spine field drops counts, so coordinate complete blood counts with chemotherapy; watch skin at match lines and the gluteal fold; expect mucositis and esophagitis from junctions or exit dose. Very young children : delay or avoid CSI when protocols allow, because myelination is incomplete. Do not teach that every infant brain tumor receives CSI on the day of diagnosis.

TBI is a systemic radiation conditioning tool for some HSCT regimens (selected leukemias, some immunodeficiencies). It is not routine for solid tumors. Acute effects are skin, parotitis, diarrhea, mucositis, and pancytopenia on top of conditioning. Late effects are growth, cataracts, endocrine failure, infertility, and secondary cancer. Nurse TBI like a radiation-plus-transplant problem: mouth care, skin, and a fertility footnote that should have been written before day −7. The dedicated HSCT chapter owns graft and veno-occlusive-disease detail; here the point is that TBI is radiation the whole body sees.

I-131-MIBG: radiation safety is the nursing plan

I-131-MIBG is a norepinephrine-analog radiopharmaceutical taken up by MIBG-avid neuroblastoma . It is not first-line therapy for a tiny perinatal adrenal mass (see the neuroblastoma chapter). When it is used for refractory avid disease, the child becomes a radiation source.

Principles— follow radiation-safety orders ; do not memorize a single isolation-day number as ONCC fact. Isolation length depends on administered activity, excretion, and the radiation safety officer's measurements.

Thyroid blockade with potassium iodide starts before the dose so free iodide does not irradiate the thyroid. Missed iodide is a preventable late effect. It belongs on the medication administration record like any other time-critical drug.

Radiation isolation in a designated room. Time, distance, and shielding protect staff and caregivers. Pregnant visitors are typically excluded. Caregiver exposure limits and film badges or electronic dosimeters are not optional etiquette.

Contamination control : urine, stool, vomit, sweat, and saliva are radioactive. Gloves, gowns, shoe covers, and designated waste. Spills are radiation events, not housekeeping tickets.

Catheters and diapers are radioactive waste . Many programs place a urinary catheter so urine is a closed, measurable source instead of soaked diapers. If diapers are used, they go in radioactive waste, not the regular trash or home laundry. Do not rinse radioactive diapers in the family bathroom.

Myelosuppression can be severe; some children have stem-cell backup. Hydration to flush excreted isotope follows the protocol.

Teach the family that hugging time is prescribed by physics, not by how much they miss the child. Video and the doorway are love.

A 5-year-old in a CSI mask who must be NPO for anesthesia, a 7-year-old sleepy two weeks after cranial radiation, and a toddler behind an MIBG door with potassium iodide on the MAR and diapers in the radioactive barrel are the three pictures. Photons versus Bragg-peak protons, daily immobilization, acute skin/mucosa/somnolence, late growth/endocrine/cognition/second cancer, CSI and TBI, and MIBG isolation without a fake day count will carry Domain III.B.6.

Loading diagram... Pediatric radiation modalities and I-131-MIBG safety